Ciclesonide ( DrugBank: Ciclesonide )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 84 | Sarcoidosis | 1 |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000013831 | 2014/04/30 | 30/04/2014 | Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation | Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation - Effect of inhaled corticosteroid therapy on pulmonary sarcoidosis | Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT. | inhaled ciclesonide (400maicrogram, twice daily, for three months) | Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan | NULL | Recruiting | 20years-old | 80years-old | Male and Female | 40 | Not selected | Japan |